These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15634640)
1. [16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics]. Lavelle F; Bull Cancer; 2004 Dec; 91(12):985-8. PubMed ID: 15634640 [No Abstract] [Full Text] [Related]
2. EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics: mechanisms of targeting for cancer treatment. Fakorede A IDrugs; 2008 Dec; 11(12):857-8. PubMed ID: 19051142 [No Abstract] [Full Text] [Related]
3. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080 [TBL] [Abstract][Full Text] [Related]
4. Promising advances in the treatment of malignant pancreatic endocrine tumors. Jensen RT; Delle Fave G N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243 [No Abstract] [Full Text] [Related]
5. [Novelties in the treatment for advanced renal-cell cancer]. Maráz A Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023 [TBL] [Abstract][Full Text] [Related]
6. mTOR pathway inhibitors in cancer therapy: moving past rapamycin. Wacheck V Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456 [No Abstract] [Full Text] [Related]
7. Tyrosine kinases as targets for cancer therapy. Krause DS; Van Etten RA N Engl J Med; 2005 Jul; 353(2):172-87. PubMed ID: 16014887 [No Abstract] [Full Text] [Related]
12. American Association for Cancer Research--99th Annual Meeting. Clinical and preclinical data on promising therapeutics. Karger GA; Lee W IDrugs; 2008 Jun; 11(6):415-7. PubMed ID: 18509781 [No Abstract] [Full Text] [Related]
14. [Antihormonal therapy in breast cancer and mTOR inhibitors]. Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994 [TBL] [Abstract][Full Text] [Related]
15. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177 [TBL] [Abstract][Full Text] [Related]
16. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610 [TBL] [Abstract][Full Text] [Related]
17. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Carraway H; Hidalgo M Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929 [TBL] [Abstract][Full Text] [Related]
18. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557 [TBL] [Abstract][Full Text] [Related]
19. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867 [TBL] [Abstract][Full Text] [Related]
20. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? Cappuzzo F J Natl Cancer Inst; 2005 Jun; 97(12):868-9. PubMed ID: 15956643 [No Abstract] [Full Text] [Related] [Next] [New Search]